Press release archive - GSK
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category. Press releases issued by our local operating companies can be viewed on our market websites.
GSK plc (GSK) Latest Stock News & Headlines - Yahoo Finance
Get the latest GSK plc (GSK) stock news and headlines to help you in your trading and investing decisions.
Next stage in GSK’s Zantac defense gets underway today
Jan 22, 2024 · GSK has reached an agreement that it says will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused cancer. Developments in...
GSK, Merck and Pfizer in Ab&B's sights as biotech files for IPO
3 days ago · Currently, GSK’s Shingrix is the only recombinant vaccine against herpes zoster, also known as shingles, approved for use in China. However, Ab&B’s chances of launching the second recombinant ...
Press releases | GSK US
GSK announces positive results from phase III trial of Nucala (mepolizumab) in COPD. GSK announced results of MATINEE, evaluating Nucala, a monoclonal antibody that targets interleukin-5 (IL-5) in adults with COPD. Download (PDF, 429.6KB)
GSK plc (GSK) Latest Press Releases & Corporate News - Yahoo …
Get the latest GSK plc (GSK) stock news and headlines to help you in your trading and investing decisions.
GSK enters agreement to acquire IDRx, Inc. | GSK
Jan 13, 2025 · Acquisition adds to GSK’s growing portfolio in gastrointestinal (GI) cancers GSK to pay up to $1.15 billion GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) today announced that they have entered into an agreement under which GSK will acquire IDRx, a Boston-based, clinical-stage biopharmaceutical company dedicated to developing precision ...
GSK to Buy US Biotech Firm IDRx for up to $1.15 Billion - U.S. News
Jan 13, 2025 · US News is a recognized leader in college, grad school, hospital, mutual fund, and car rankings. ... -British drugmaker GSK said on Monday that it would pay up to $1.15 billion to buy Boston-based ...
GSK to Pay Over $2 Billion in Bid to End Most U.S. Zantac Lawsuits ...
Oct 9, 2024 · GSK agreed to pay more than $2 billion to settle almost all remaining liability cases in the U.S. over allegations its discontinued heartburn medicine Zantac causes cancer.
GSK shares tumble 9% after 70,000 Zantac lawsuits allowed to …
Jun 3, 2024 · Shares of GSK dropped more than 9% on Monday, after a Delaware judge allowed more than 70,000 lawsuits alleging its discontinued heartburn drug Zantac caused cancer, to go forward, in a blow for...